Grace Therapeutics, Inc
GRCE2.948USD
+0.078+2.72%
交易中 （美东）报价延迟15分钟
40.44M总市值
亏损市盈率 TTM
关于 Grace Therapeutics, Inc 公司
Grace Therapeutics, Inc.（前身为 Acasti Pharma Inc.）是一家后期生物制药公司，其候选药物用于治疗罕见病和孤儿病。其治疗产品线包括三种临床阶段候选药物，由在不同司法管辖区内已授予和正在申请的 40 多项专利的知识产权组合提供支持。其主要候选药物 GTX-104 是一种临床阶段的新型尼莫地平注射剂型，正在开发用于动脉瘤性蛛网膜下腔出血 (aSAH) 患者的静脉 (IV) 输注，以满足重大未满足的医疗需求。GTX-104 可在重症监护室中方便地静脉注射尼莫地平，无需对昏迷或吞咽困难的患者进行鼻胃管给药。该公司其他在研候选药物包括 GTX-102，这是一种用于治疗毛细血管扩张性共济失调症的口腔黏膜倍他米松喷雾剂，以及 GTX-101，这是一种用于治疗带状疱疹后神经痛的局部生物粘合成膜布比卡因喷雾剂。
公司简介
公司代码GRCE
公司名称Grace Therapeutics, Inc
上市日期Mar 07, 2013
CEOMr. Prashant Kohli
员工数量- -
证券类型Ordinary Share
年结日Mar 07
公司地址103 Carnegie Center
城市PRINCETON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编08540
电话16093221602
网址https://www.gracetx.com/
公司代码GRCE
上市日期Mar 07, 2013
CEOMr. Prashant Kohli
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
Mr. Robert J. Delaversano
Mr. Robert J. Delaversano
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
Dr. R. Loch Macdonald, M.D., Ph.D.
Dr. R. Loch Macdonald, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. S. George Kottayil
Dr. S. George Kottayil
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. A. Brian Davis
Mr. A. Brian Davis
Independent Director
Independent Director
--
--
Ms. Carrie D'Andrea
Ms. Carrie D'Andrea
Vice President - Clinical Operations
Vice President - Clinical Operations
--
--
收入明细
FY2021
暂无数据
地区USD
名称
营收
占比
Canada
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Shore Pharma LLC
9.66%
Nantahala Capital Management, LLC
8.52%
SS Pharma LLC
7.80%
AIGH Capital Management, LLC.
6.07%
Rajitha Grace 2018 Irrevocable Trust
5.65%
Other
62.29%
持股股东
持股股东
占比
Shore Pharma LLC
9.66%
Nantahala Capital Management, LLC
8.52%
SS Pharma LLC
7.80%
AIGH Capital Management, LLC.
6.07%
Rajitha Grace 2018 Irrevocable Trust
5.65%
Other
62.29%
股东类型
持股股东
占比
Corporation
23.11%
Hedge Fund
11.61%
Individual Investor
7.17%
Private Equity
6.07%
Investment Advisor/Hedge Fund
4.62%
Research Firm
3.59%
Investment Advisor
2.20%
Bank and Trust
0.02%
Other
41.60%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
46
7.78M
66.51%
+1.05M
2025Q1
48
7.92M
57.31%
+1.83M
2024Q4
47
5.99M
59.05%
-359.46K
2024Q3
42
6.02M
59.34%
-98.00K
2024Q2
44
6.05M
59.66%
+810.14K
2024Q1
42
2.77M
33.70%
+1.44M
2023Q4
43
2.08M
26.30%
+647.61K
2023Q3
42
2.06M
26.16%
+1.15M
2023Q2
48
913.80K
16.66%
+138.89K
2023Q1
55
824.75K
11.14%
+317.32K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Shore Pharma LLC
1.19M
8.59%
--
--
Jul 31, 2024
Nantahala Capital Management, LLC
1.18M
8.52%
+1.18M
--
Mar 31, 2025
SS Pharma LLC
931.74K
6.74%
--
--
Jul 31, 2024
AIGH Capital Management, LLC.
983.17K
7.11%
+596.62K
+154.34%
Mar 31, 2025
Rajitha Grace 2018 Irrevocable Trust
781.59K
5.65%
--
--
Jul 31, 2024
BofA Global Research (US)
494.70K
3.58%
--
--
Mar 31, 2025
Kottayil (George)
494.70K
3.58%
--
--
Jul 31, 2024
Kavuru (Vimal)
426.32K
3.08%
--
--
Jul 31, 2024
Adar1 Capital Management LLC
343.51K
2.48%
-430.12K
-55.60%
Mar 31, 2025
Worth Venture Partners, LLC
339.21K
2.45%
+204.68K
+152.14%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Unusual Whales Subversive Republican Trading ETF
0%
Unusual Whales Subversive Republican Trading ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Aug 27, 2021
Merger
8<1
Aug 27, 2021
Merger
8<1
公告日期
类型
比率
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Jul 07, 2023
Merger
6<1
Aug 27, 2021
Merger
8<1
Aug 27, 2021
Merger
8<1
Aug 27, 2021
Merger
8<1
Aug 27, 2021
Merger
8<1
